Imatinib Attenuates Diabetes-Associated Atherosclerosis

Objective—Diabetes is associated with accelerated atherosclerosis, the major factor contributing to increased mortality and morbidity in the diabetic population. The molecular mechanisms by which diabetes promotes atherosclerosis are not fully understood. Platelet-derived growth factor has been shown to play a major role in the pathology of vascular diseases, but whether it plays a role in atherosclerosis associated with diabetes remains unknown. The aims of this study were to assess whether platelet-derived growth factor–dependent pathways are involved in the development of diabetes-induced atherosclerosis and to determine the effects of platelet-derived growth factor receptor antagonism on this disorder. Methods and Results—Diabetes was induced by injection of streptozotocin in 6-week-old apolipoprotein E knockout mice. Diabetic animals received treatment with a tyrosine kinase inhibitor that inhibits platelet-derived growth factor action, imatinib (STI-571, 10 mg/kg per day), or no treatment for 20 weeks. Nondiabetic apolipoprotein E knockout mice served as controls. Induction of diabetes was associated with a 5-fold increase in plaque area in association with an increase in aortic platelet-derived growth factor-B expression and platelet-derived growth factor-β receptor phosphorylation as well as other prosclerotic and proinflammatory cytokines. Imatinib treatment prevented the development of atherosclerotic lesions and diabetes-induced inflammatory cytokine overexpression in the aorta. Conclusions—Tyrosine kinase inhibition with imatinib appears to be a novel therapeutic option to retard the development of atherosclerosis, specifically in the context of diabetes.

[1]  François Mach,et al.  Inflammation and Atherosclerosis , 2004, Herz.

[2]  E. Buchdunger,et al.  Selective Tyrosine Kinase Inhibitor for the Platelet-Derived Growth Factor Receptor In Vitro Inhibits Smooth Muscle Cell Proliferation After Reinjury of Arterial Intima In Vivo , 1999, Cardiovascular Drugs and Therapy.

[3]  Richard G. W. Anderson,et al.  LRP: Role in Vascular Wall Integrity and Protection from Atherosclerosis , 2003, Science.

[4]  I. Raz,et al.  Hyperglycemia and Cardiovascular Disease in Type 2 Diabetes Mellitus: Evidence-based Approach to Primary and Secondary Prevention , 2003 .

[5]  C. Betsholtz,et al.  Blockade of platelet-derived growth factor or its receptors transiently delays but does not prevent fibrous cap formation in ApoE null mice. , 2002, The American journal of pathology.

[6]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[7]  M. Cooper,et al.  Prevention of Accelerated Atherosclerosis by Angiotensin-Converting Enzyme Inhibition in Diabetic Apolipoprotein E–Deficient Mice , 2002, Circulation.

[8]  V. Paradis,et al.  Effects and Regulation of Connective Tissue Growth Factor on Hepatic Stellate Cells , 2002, Laboratory Investigation.

[9]  S. Nishikawa,et al.  Functional Blockade of Platelet-Derived Growth Factor Receptor-&bgr; but Not of Receptor-&agr; Prevents Vascular Smooth Muscle Cell Accumulation in Fibrous Cap Lesions in Apolipoprotein E–Deficient Mice , 2001, Circulation.

[10]  T. Rabelink,et al.  In vitro evidence for differential involvement of CTGF, TGFbeta, and PDGF-BB in mesangial response to injury. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  M. Cooper,et al.  Vascular expression of angiotensin type 2 receptor in the adult rat: influence of angiotensin II infusion , 2001, Journal of hypertension.

[12]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[13]  G. Mcmahon,et al.  Weekly Dosing With the Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor SU9518 Significantly Inhibits Arterial Stenosis , 2001, Circulation research.

[14]  G. Jerums,et al.  Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. , 2000, Journal of the American Society of Nephrology : JASN.

[15]  Gordon A Ferns,et al.  Endogenous Neutralizing Antibodies Against Platelet-Derived Growth Factor-AA Inhibit Atherogenesis in the Cholesterol-Fed Rabbit , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[16]  C. Heldin,et al.  PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. , 2001, Nature cell biology.

[17]  K. Yokote,et al.  Increased atherogenesis in Otsuka Long-Evans Tokushima fatty rats before the onset of diabetes mellitus: association with overexpression of PDGF beta-receptors in aortic smooth muscle cells. , 2000, Atherosclerosis.

[18]  H Li,et al.  PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. , 2000, Nature cell biology.

[19]  M. Makuuchi,et al.  Angiotensin II stimulates platelet-derived growth factor-B chain expression in newborn rat vascular smooth muscle cells and neointimal cells through Ras, extracellular signal-regulated protein kinase, and c-Jun N-terminal protein kinase mechanisms. , 1999, Circulation research.

[20]  E. Buchdunger,et al.  Prevention of cardiac allograft arteriosclerosis by protein tyrosine kinase inhibitor selective for platelet-derived growth factor receptor. , 1999, Circulation.

[21]  M. Laakso,et al.  Hyperglycemia and cardiovascular disease in type 2 diabetes. , 1999, Diabetes.

[22]  L. Lau,et al.  Fisp12/Mouse Connective Tissue Growth Factor Mediates Endothelial Cell Adhesion and Migration through Integrin αvβ3, Promotes Endothelial Cell Survival, and Induces Angiogenesis In Vivo , 1999, Molecular and Cellular Biology.

[23]  J. Koziol,et al.  The role of alpha and beta platelet-derived growth factor receptor in the vascular response to injury in nonhuman primates. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[24]  C. Heldin,et al.  Mechanism of action and in vivo role of platelet-derived growth factor. , 1999, Physiological reviews.

[25]  M. Taubman,et al.  Platelet-derived Growth Factor-specific Regulation of theJE Promoter in Rat Aortic Smooth Muscle Cells* , 1998, The Journal of Biological Chemistry.

[26]  A. Schmidt,et al.  Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.

[27]  E. Buchdunger,et al.  Inhibition of platelet‐derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  W. März,et al.  Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. , 1997, Circulation.

[29]  E. Anggard,et al.  Endogenously elicited antibodies to platelet derived growth factor‐BB and platelet cytosolic protein inhibit aortic lesion development in the cholesterol‐fed rabbit , 1997, International journal of experimental pathology.

[30]  Y. Okuda,et al.  Increased production of PDGF by angiotensin and high glucose in human vascular endothelium. , 1996, Life sciences.

[31]  M. Kawakami,et al.  Enhanced Expression of Platelet-Derived Growth Factor-β Receptor by High Glucose Involvement of Platelet-Derived Growth Factor in Diabetic Angiopathy , 1996, Diabetes.

[32]  A. Bennett,et al.  Increased expression of genes for platelet-derived growth factor in circulating mononuclear cells of hypercholesterolemic patients. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[33]  H. Rasmussen,et al.  PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products. , 1995, Kidney international.

[34]  J. Hodgin,et al.  A noninvasive computerized tail-cuff system for measuring blood pressure in mice. , 1995, Hypertension.

[35]  D. Máthé.  Dyslipidemia and diabetes: animal models. , 1995, Diabete & metabolisme.

[36]  C. Alpers,et al.  Renal injury from angiotensin II-mediated hypertension. , 1992, Hypertension.

[37]  G. Striker,et al.  Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[38]  B. Rollins,et al.  JE mRNA accumulates rapidly in aortic injury and in platelet-derived growth factor-stimulated vascular smooth muscle cells. , 1992, Circulation research.

[39]  J. Manson,et al.  A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. , 1991, Archives of internal medicine.

[40]  H. Abboud,et al.  Endothelin stimulates PDGF secretion in cultured human mesangial cells. , 1990, Kidney international.

[41]  L. Niskanen,et al.  5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. , 1990, Circulation.

[42]  H. Abboud,et al.  Platelet-derived growth factor synthesis in mesangial cells: induction by multiple peptide mitogens. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[43]  M. Laakso,et al.  Diabetes and atherosclerosis: an epidemiologic view. , 1987, Diabetes/metabolism reviews.

[44]  P. McNamara,et al.  Morbidity and Mortality in Diabetics In the Framingham Population: Sixteen Year Follow-up Study , 1974, Diabetes.